Relapsing optic neuritis and isolated transverse myelitis are the predominant clinical phenotypes for patients with antibodies to myelin oligodendrocyte glycoprotein in India

Multiple Sclerosis Journal - Experimental, Translational and Clinical

Volumn 2, Issue , 2016, Pages

  Pandit, Lekha ^a   Sato, Douglas Kazutoshi ^b,c   Mustafa, Sharik ^a   Takahashi, Toshiyuki ^d   D’Cunha, Anitha ^a   Malli, Chaithra ^a   Sudhir, Akshatha ^a   Fujihara, Kazuo ^b  

^a NITTE UNIVERSITY   (India)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^d Yonezawa National Hospital   (Japan)

Author keywords

aquaporin 4 antibody; India; myelin oligodendrocyte glycoprotein antibody; myelitis; Optic neuritis

Indexed keywords

AQUAPORIN 4 ANTIBODY; BETA INTERFERON; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; STEROID;

ACUTE DISSEMINATED ENCEPHALOMYELITIS; ADULT; ARTICLE; DEMYELINATING DISEASE; DISEASE DURATION; EXPANDED DISABILITY STATUS SCALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INDIA; LHERMITTE DUCLOS DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MYELITIS; MYELOOPTIC NEUROPATHY; OPTIC CHIASM; OPTIC NEURITIS; PHENOTYPE; PRIORITY JOURNAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; YOUNG ADULT;

EID: 85032909249     PISSN: None     EISSN: 20552173     Source Type: Journal    
DOI: 10.1177/2055217316675634     Document Type: Article

References (14)

1. Kitley J, Woodhall M, Waters P. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology 2012; 79: 1273–1277.
2. Woodhall M, Çoban A, Waters P. Glycine receptor and myelin oligodendrocyte glycoprotein antibodies in Turkish patients with neuromyelitis optica. J Neurol Sci 2013; 335: 221–223.
3. Sato DK, Callegaro D, Lana-Peixoto MA. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 2014; 82: 474–481.
4. Ramanathan S, Reddel SW, Henderson A. Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis. Neurol Neuroimmunol Neuroinflamm 2014; 1: e40. doi: 10.1212/NXI.0000000000000040.
5. Pröbstel AK, Rudolf G, Dornmair K. Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype. J Neuroinflamm 2015; 12: 46. doi: 10.1186/s12974-015-0256-1.
6. Fernandez-Carbonell C, Vargas-Lowy D, Musallam A. Clinical and MRI phenotype of children with MOG antibodies. Mult Scler 2016; 22: 174–184.
7. Siritho S, SatoK D, Kaneko K. The clinical spectrum associated with myelin oligodendrocyte glycoprotein antibodies (anti-MOG-Ab) in Thai patients. Mult Scler 2016; 22: 964–968.
8. Wingerchuk DM, Lennon VA, Pittock SJ. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66: 1485–1489.
9. Rostasy K, Mader S, Schanda K. Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis. Arch Neurol 2012; 69: 752–756.
10. Chalmoukou K, Alexopoulos H, Akrivou S. Anti-MOG antibodies are frequently associated with steroid-sensitive recurrent optic neuritis. Neurol Neuroimmunol Neuroinflamm 2015; 2: 2e131.
11. Wingerchuck DM, Banwell B, Bennet JL. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015; 85: 177–189.
12. Akaishi T, Sato DK, Nakashima I. MRI and retinal abnormalities in isolated optic neuritis with myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies: a comparative study. J Neurol Neurosurg Psychiatry 2016; 87: 446–448.
13. Tanaka M, Tanaka K, Komori M. Interferon-beta (1b) treatment in neuromyelitis optica. Eur Neurol 2009; 62: 167–170.
14. Palace J, Leite MI, Nairne A. Interferon beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch Neurol 2010; 67: 1016–1017.